VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$7.46Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $384,115,392.00
EPSttm : -3.66
Verastem, Inc.
$7.46
2.33%$0.17Float Short %
20.43
Margin Of Safety %
Put/Call OI Ratio
0.06
EPS Next Q Diff
0.57
EPS Last/This Y
0.87
EPS This/Next Y
1.3
Price
7.46
Target Price
15.75
Analyst Recom
1
Performance Q
29.97
Relative Volume
2.77
Beta
0.85
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | VSTM | 4.78 | 0.17 | 0.06 | 4147 |
| 2025-04-15 | VSTM | 4.82 | 0.14 | 0.00 | 4145 |
| 2025-04-16 | VSTM | 4.97 | 0.13 | 0.00 | 4336 |
| 2025-04-17 | VSTM | 5.72 | 0.12 | 0.02 | 4554 |
| 2025-04-18 | VSTM | 5.74 | 0.12 | 0.00 | 4554 |
| 2025-04-21 | VSTM | 6.21 | 0.04 | 0.00 | 8720 |
| 2025-04-22 | VSTM | 7.03 | 0.03 | 0.18 | 9231 |
| 2025-04-23 | VSTM | 7.11 | 0.05 | 0.00 | 9924 |
| 2025-04-24 | VSTM | 7.52 | 0.03 | 0.18 | 14902 |
| 2025-04-25 | VSTM | 7.5 | 0.038946085071796 | 0.49532710280374 | 15339 |
| 2025-04-28 | VSTM | 6.99 | 0.058975036322811 | 0.18768768768769 | 16035 |
| 2025-04-29 | VSTM | 6.97 | 0.06 | 0.45 | 16221 |
| 2025-04-30 | VSTM | 7.49 | 0.06 | 1.33 | 16308 |
| 2025-05-01 | VSTM | 7.41 | 0.07 | 0.02 | 16566 |
| 2025-05-02 | VSTM | 7.43 | 0.07 | 0.05 | 16612 |
| 2025-05-05 | VSTM | 7.01 | 0.07 | 0.06 | 16671 |
| 2025-05-06 | VSTM | 6.52 | 0.08 | 0.72 | 16880 |
| 2025-05-07 | VSTM | 6.68 | 0.08 | 0.16 | 16954 |
| 2025-05-08 | VSTM | 6.94 | 0.08 | 0.04 | 16944 |
| 2025-05-09 | VSTM | 7.16 | 0.08 | 0.00 | 17272 |
| 2025-05-12 | VSTM | 7.28 | 0.06 | 0.02 | 21992 |
| 2025-05-13 | VSTM | 7.47 | 0.06 | 0.04 | 22448 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | VSTM | 4.78 | 37.8 | - | -2.35 |
| 2025-04-15 | VSTM | 4.81 | 37.8 | - | -2.35 |
| 2025-04-16 | VSTM | 4.97 | 37.8 | - | -2.35 |
| 2025-04-17 | VSTM | 5.74 | 37.8 | - | -2.35 |
| 2025-04-18 | VSTM | 5.74 | 37.8 | - | -2.35 |
| 2025-04-21 | VSTM | 6.20 | 37.8 | - | -2.35 |
| 2025-04-22 | VSTM | 7.04 | 37.8 | - | -2.35 |
| 2025-04-23 | VSTM | 7.12 | 37.8 | - | -2.35 |
| 2025-04-24 | VSTM | 7.51 | 37.8 | - | -2.35 |
| 2025-04-25 | VSTM | 7.50 | 37.8 | - | -2.79 |
| 2025-04-28 | VSTM | 6.99 | 20.9 | - | -2.79 |
| 2025-04-29 | VSTM | 6.97 | 20.9 | - | -2.79 |
| 2025-04-30 | VSTM | 7.49 | 20.9 | - | -2.79 |
| 2025-05-01 | VSTM | 7.43 | 20.9 | - | -2.79 |
| 2025-05-02 | VSTM | 7.43 | 20.9 | - | -2.79 |
| 2025-05-05 | VSTM | 7.01 | 20.9 | - | -2.79 |
| 2025-05-06 | VSTM | 6.52 | 20.9 | - | -2.79 |
| 2025-05-07 | VSTM | 6.69 | 20.9 | - | -2.79 |
| 2025-05-08 | VSTM | 6.93 | 20.9 | - | -2.79 |
| 2025-05-09 | VSTM | 7.18 | 20.9 | - | -2.79 |
| 2025-05-12 | VSTM | 7.29 | 20.9 | - | -2.79 |
| 2025-05-13 | VSTM | 7.46 | 20.9 | - | -2.79 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-15 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-16 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-17 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-18 | VSTM | -0.23 | 52.00 | 17.28 |
| 2025-04-21 | VSTM | -0.23 | 51.55 | 17.28 |
| 2025-04-22 | VSTM | -0.23 | 51.55 | 17.28 |
| 2025-04-23 | VSTM | -0.23 | 51.55 | 17.28 |
| 2025-04-24 | VSTM | -0.23 | 51.55 | 17.28 |
| 2025-04-25 | VSTM | -0.23 | 51.55 | 17.28 |
| 2025-04-28 | VSTM | -0.23 | 51.56 | 19.33 |
| 2025-04-29 | VSTM | -0.23 | 51.56 | 19.33 |
| 2025-04-30 | VSTM | -0.23 | 51.56 | 19.33 |
| 2025-05-01 | VSTM | -0.23 | 51.56 | 19.33 |
| 2025-05-02 | VSTM | -0.23 | 51.56 | 19.33 |
| 2025-05-05 | VSTM | -0.23 | 49.44 | 19.33 |
| 2025-05-06 | VSTM | -0.23 | 49.44 | 19.33 |
| 2025-05-07 | VSTM | -0.26 | 49.44 | 18.99 |
| 2025-05-08 | VSTM | -0.26 | 49.44 | 18.99 |
| 2025-05-09 | VSTM | -0.26 | 49.44 | 18.99 |
| 2025-05-12 | VSTM | -0.23 | 21.71 | 20.43 |
| 2025-05-13 | VSTM | -0.23 | 21.71 | 20.43 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.33
Avg. EPS Est. Current Quarter
-0.61
Avg. EPS Est. Next Quarter
-0.76
Insider Transactions
-0.23
Institutional Transactions
21.71
Beta
0.85
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
4
Fair Value
Quality Score
7
Growth Score
37
Sentiment Score
89
Actual DrawDown %
87.4
Max Drawdown 5-Year %
-96.2
Target Price
15.75
P/E
Forward P/E
PEG
P/S
38.41
P/B
P/Free Cash Flow
EPS
-3.49
Average EPS Est. Cur. Y
-2.79
EPS Next Y. (Est.)
-1.5
Target Price Estimates Raised
3
Target Price Estimates Lowered
Profit Margin
-1306.36
Relative Volume
2.77
Return on Equity vs Sector %
428.5
Return on Equity vs Industry %
445.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.45
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading